Despite the success of PPIs in managing many aspects of GERD, several unmet needs persist, including advanced EE, NERD, overnight heartburn, maintenance therapy, and refractory GERD.1
P-CABs like VONOprazan offer solutions to many of the disadvantages and limitations of PPIs:1
Unlike PPIs, P-CABs are not prodrugs and do not require activation in parietal cells, leading to immediate action and acid control within the first day of treatment.
P-CABs have a slower dissociation from the proton pump, providing up to 24 hours of action and effective acid suppression throughout the day and night.
VONOprazan shows superior acid suppression, symptom relief, and esophagitis healing compared to PPIs in PPI-refractory GERD.
It offers meal-independent antisecretory activity.
Relief from GERD symptoms was achieved in 89% of patients within one month, with 82% maintaining symptom relief after one year without further treatment.
Given these benefits, VONOprazan or other P-CABs should be considered for difficult-to-treat acid-related conditions and unmet needs, where the benefit-to-risk ratio is most favorable.1
Vono 20-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
